NCT06705387 Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE
| NCT ID | NCT06705387 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | University of Colorado, Denver |
| Condition | Eosinophilic Esophagitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 72 participants |
| Start Date | 2024-12-23 |
| Primary Completion | 2026-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 72 participants in total. It began in 2024-12-23 with a primary completion date of 2026-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to \[primary purpose: e.g., learn if intervention or health behavior can treat, prevent, diagnose etc.\] in \[describe participant population/primary condition; could include any of the following: sex/gender, age groups, healthy volunteers\]. The main question\[s\] it aims to answer \[is/are\]: Does dupilumab or swallowed topical fluticasone improve the diameter of the esophagus more? Does dupilumab or swallowed topical fluticasone reduce inflammation in the esophagus more? Are comparative effective clinical trials feasible in this patient population? Researchers will compare dupilumab 300 mg weekly compared to swallowed fluticasone to see if there is a difference in treatment response. Participants will be asked to: * Be randomized to either dupilumab sq weekly or swallowed topical fluticasone twice daily. * Participate in 8 study visits over 52 weeks * Complete questionnaires * Have an endoscopy with biopsies and EndoFLIP measurements. * Swallow an Esophageal String Test
Eligibility Criteria
Inclusion Criteria: * Seen at CHCO for clinical care. * Age 12 - 25 years old inclusive * Weight ≥40 kg at the time of screening visit * Confirmed EoE as diagnosed by biopsy with eosinophils ≥15 eosinophils/hpf in at least 2 esophageal regions at screening endoscopy * Report of an average of at least 2 episodes of dysphagia per week in the 4 weeks prior to screening. * Evidence of fibrostenotic features at time of screening endoscopy (grade 2 or 3 esophageal rings, stricture, delayed passage of barium tablet on fluoroscopy, and/or distensibility ≤15mm) Exclusion Criteria: * Esophageal dilation performed at index endoscopy * Patients with stricture undergoing dilation at index endoscopy may be rescreened if they meet all other eligibility criteria. * Patients with acute food impaction will not be enrolled at their therapeutic endoscopy but are eligible for enrollment subsequently if they meet all other eligibility criteria. * Eligible patients on current STCs can be enrolled but need to be on stable dosing less than or equal to 440 mcg two times daily fluticasone equivalent for 3 months prior to enrollment. * Patients who have received dupilumab in the past 12 months for any indication are excluded. * Diet restrictions and PPI use must stay unchanged in the 8 weeks prior to index endoscopy and through the study period. * Patients with a fasting morning cortisol \<5 within 2 months of screening will not be enrolled. If repeat cortisol levels are normal, patients can be reconsented. * Known other esophageal disease or esophageal injury (e.g. achalasia, tracheoesophageal fistula, congenital stricture, caustic injury, history of esophageal surgery), inflammatory bowel disease, liver disease, connective tissue disorder, or bleeding disorder. * Patients with a known gelatin allergy will be excluded from EST collection.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06705387 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, up to 25 Years, studying Eosinophilic Esophagitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06705387 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06705387 currently recruiting?
Yes, NCT06705387 is actively recruiting participants. Contact the research team at michelle.landis@childrenscolorado.org for enrollment information.
Where is the NCT06705387 trial being conducted?
This trial is being conducted at Aurora, United States.
Who is sponsoring the NCT06705387 clinical trial?
NCT06705387 is sponsored by University of Colorado, Denver. The trial plans to enroll 72 participants.